Jarden weakness creates a buying opportuntiy, says Oppenheimer After Jarden reported higher than expected Q3 EPS but lower than expected organic sales, Oppenheimer expects the company's organic sales growth to reaccelerate in Q4 and 2013. The firm maintains an Outperform rating on the stock.
Jarden backs FY14 EPS guidance of 'in-line with street estimates' The company sees foreign exchange rate, excluding Venezuela, impacting FY14 revenue by $60M-$90M. The company expects to generate $650M in cash flow from operations in FY14. Management stated that the company is mindful of movements in the Euro. Currency was a mild headwind in FY14 and could have a significant impact on FY15. Comments provided during Q3 earnings conference call.